VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 02, 2007) - Chemokine Therapeutics Corp. (the “Company”) (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular diseases, announced today that the Company has completed recruitment of its Phase I/II clinical study using its lead compound CTCE-9908 with late stage cancer patients. Dosing is expected to be completed by the end of October 2007 with results reported by the end of the year.
